NORCROSS, Ga. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber , M.D., the Company's chief executive officer and chief medical officer was named Chair of the Conference for
Research to be presented demonstrates VCTE liver stiffness measurement is a surrogate for identifying portal hypertension in patients with compensated NASH cirrhosis
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be announced in early December 2017 NORCROSS, Ga. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics
The objective response rate in advanced melanoma was 62.5% (five of eight subjects) NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced the
NORCROSS, Ga. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber , M.D., the Company's chief executive officer and chief medical officer, has been named the Chair of the
Company to Host Investor Conference Call at 8:30 A.M. ET NORCROSS, Ga. , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing the results of its Phase 2b NASH-CX trial
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line Trial Results NORCROSS, Ga. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
NORCROSS, Ga. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate update via live webcast immediately following the business portion of its 2017
Dr. Peter Traber , CEO and CMO, reviews results of NASH-CX trial that demonstrated statistically significant and clinically meaningful effects in patients who had NASH cirrhosis but did not have esophageal varices Approximately 50% of all patients with NASH cirrhosis do not have esophageal varices
NORCROSS, Ga. , Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured line of credit facility with stockholder and new director Richard E. Uihlein .
